Candel therapeutics to join russell 3000® index

Needham, mass., june 11, 2024 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the company is set to join the broad-market russell 3000 index at the conclusion of the 2024 russell us indexes annual reconstitution, effective at the open of us equity markets on monday, july 1, 2024, according to a preliminary list of additions posted friday, may 24, 2024.
CADL Ratings Summary
CADL Quant Ranking